Filing summary
Entity note: The request identifies Leonabio, Inc., but the supplied Form 10-Q is for Athira Pharma, Inc. (Nasdaq: ATHA). This summary covers the filing actually provided.
Business context and reporting period
Athira is a clinical-stage biopharmaceutical company developing small-molecule therapies for neurodegenerative disorders. The report covers the quarter and nine months ended September 30, 2022; it was signed November 10, 2022. The company had no approved products and no product-sales revenue.
Financial results and liquidity
Amounts below are in millions of dollars, except per-share data.
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Research and development expense | $17.0 | $10.7 | $46.2 | $30.2 |
| General and administrative expense | $7.2 | $7.1 | $24.9 | $15.1 |
| Total operating expenses | $24.1 | $17.8 | $71.1 | $45.2 |
| Grant income | $3.0 | $2.1 | $3.9 | $6.5 |
| Other income, net | $1.0 | $0.1 | $1.7 | $0.2 |
| Net loss | $(20.2) | $(15.7) | $(65.5) | $(38.5) |
| Net loss per share | $(0.53) | $(0.42) | $(1.74) | $(1.05) |
There was no product revenue, so gross margin and revenue-based margins are not applicable. Q3 research and development costs rose 58%, primarily from fosgonimeton trial activity, higher personnel and stock-compensation costs, preclinical work, and the ATH-1020 Phase 1 trial. Nine-month general and administrative costs rose 65%, including higher personnel, legal, business-development, and insurance expenses.
Net cash used in operations was $56.8 million for the first nine months of 2022, versus $24.9 million a year earlier. Investing activities provided $33.0 million, principally reflecting maturities of securities; financing activities provided $0.5 million, mainly from option exercises. Cash, cash equivalents, and restricted cash decreased $23.3 million to $87.3 million. Total cash, cash equivalents, and investments were $260.0 million at September 30, 2022; management estimated this would fund operating and capital needs for at least 12 months following the report date.
Total liabilities were $11.9 million, primarily operating lease liabilities; the filing reports no debt borrowing balance. Lease liabilities totaled $2.0 million, with $2.4 million of undiscounted payments remaining. Stockholders’ equity was $262.2 million. Available-for-sale securities had $4.1 million of aggregate unrealized losses at quarter-end, reflected in accumulated other comprehensive loss.
Material changes and operating developments
- Nine-month net loss increased by $27.0 million year over year as operating expenses expanded and grant income declined.
- NIH grant income for the nine months fell $2.6 million, attributed to fewer qualifying reimbursable expenses after the ACT-AD topline readout. Q3 grant income included $1.3 million recognized for earlier qualifying costs following NIH budget carryover approval.
- Interest and other income increased, mainly due to higher interest rates on the investment portfolio.
- In June 2022, ACT-AD’s primary endpoint was not met under the protocol analysis. A post hoc subgroup analysis of patients not taking background acetylcholinesterase inhibitors showed numerical improvements that were not statistically significant; the company cautioned that post hoc analyses do not establish efficacy.
- In September 2022, Athira amended LIFT-AD to focus on patients not receiving background acetylcholinesterase inhibitors. In October, an independent monitoring committee recommended continuing after an unblinded interim efficacy and futility analysis. Athira targeted enrollment completion in mid-2023 and topline results in early 2024.
Outlook, risks, and contingencies
Management expects losses and research and development spending to increase as clinical trials, open-label extensions, pipeline work, staffing, manufacturing preparation, and legal costs continue. The company expects to need substantial additional funding over time and cannot assure profitability or positive operating cash flow. Additional financing may dilute shareholders or impose restrictive terms; funding may not be available when needed.
A special board committee found that former CEO Leen Kawas altered images in her dissertation and at least four research papers, and that certain challenged papers were cited in company communications and applications. WSU’s separate review remained ongoing, with timing and outcome uncertain. Securities class-action claims and consolidated shareholder derivative actions related to the research allegations were pending. The company recorded no liability for these matters because loss was not considered reasonably estimable; an unfavorable outcome could materially affect the business and financial condition.
Key risks include clinical failure or delay, particularly after ACT-AD missed its primary endpoint; uncertainty about whether the apparent subgroup effect will be confirmed; trial enrollment and execution; regulatory approval; reliance on third-party manufacturers and research organizations; patent and license challenges, including the WSU-licensed dihexa portfolio; litigation and reputational harm; COVID-19 disruption; competition; and future financing needs. The company reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Athira Pharma’s, not Leonabio’s.
- Review final LIFT-AD enrollment, the amended study population, and the topline results expected in early 2024; distinguish interim or subgroup findings from confirmatory efficacy evidence.
- Track WSU’s research review, the status and potential exposure of securities and derivative litigation, and any impact on licensed intellectual property or grants.
- Assess cash burn against the stated minimum 12-month runway and any future financing, collaboration, or cost-reduction plans.
- Reconcile cash and investments, including security maturities and unrealized losses, and monitor the growth in operating expenses and stock-based compensation.